StemCells plans first spinal cord trial in Switzerland; Gen-Probe building European HQ;

 @FierceBiotech: Otsuka plots $2.8B IPO. News | Follow @FierceBiotech

> StemCells is planning to host its first trial of a new stem cell therapy for spinal cord injuries in Switzerland. The developer says it will ask Swiss officials for their OK to recruit about a dozen patients with spinal cord injuries incurred in the previous three to 12 months. To date, much of the work in the field has centered on new, acute cases. The StemCell treatment relies on nerve stem cells, which proved effective in a rodent study. Report

> California-based Gen-Probe says it will build a European headquarters in Manchester. "We are reliant on having a talented pool of scientists to draw from and Manchester is excellent for that, and it has excellent communication and infrastructure links," says Mick Slater, Gen-Probe's finance director of European operations. Report

> Ablynx says it is in line for €3 million in milestones from Boehringer Ingelheim. Story

And Finally... A new study involving 20,000 healthy women has concluded that job stress increased the risk of a heart attack for 88 percent. "Job strain for this study included people who felt they were in jobs with little or no decision making, they were very demanding jobs, and in particular didn't allow them to use their individual creativity," said Dr. Jennifer Ashton. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.